The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice
Authors:
- 28 September 2007
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 26 (11-12) , 1537-1542
Abstract
Failure of first line and subsequent Helicobacter pylori eradication therapy is a significant problem and alternative treatments are few. To evaluate the efficacy of a rifabutin-based triple therapy in clinical practice and determine the optimal strategy for its use. Patients referred after first or subsequent treatment failure were prescribed rifabutin triple therapy consisting of standard dose proton pump inhibitor, amoxicillin 1 g and rifabutin 150 mg each b.d. for 10 days. In 67 patients, the main indications for treatment were dyspepsia (55%), peptic ulcer disease (24%) and increased gastric cancer risk (18%). The median number of previous treatments was 2 (range: 1-9). Eradication of Helicobacter pylori was achieved in 76% (48/63) per protocol and 72% (48/67) on an intention-to-treat basis. When used as second line therapy, 95% (18/19) achieved eradication compared with 68% (30/44) when two or more previous treatments had been used (P = 0.03). Outcome was independent of age, ethnicity, gender or indication for treatment. Adverse events were reported in 10%. Rifabutin triple therapy is a well tolerated and effective second line therapy in the treatment of persistent Helicobacter pylori; however, its efficacy decreases with increasing number of failed previous therapies.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infectionBMC Gastroenterology, 2007
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Third‐line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failuresAlimentary Pharmacology & Therapeutics, 2006
- Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 2006
- Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failureAlimentary Pharmacology & Therapeutics, 2005
- Relapse and Acquired Rifampin Resistance in HIV-Infected Patients with Tuberculosis Treated with Rifampin- or Rifabutin-Based Regimens in New York City, 1997-2000Clinical Infectious Diseases, 2005
- Rifabutin-Associated Panuveitis with Retinal Vasculitis in Pulmonary TuberculosisOcular Immunology and Inflammation, 2005
- Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patientsAlimentary Pharmacology & Therapeutics, 2004
- High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapyInternational Journal of Antimicrobial Agents, 2004
- Seven‐day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazoleAlimentary Pharmacology & Therapeutics, 1999